Journal of Medicinal Chemistry
Article
(7) Copeland, R. A. The dynamics of drug-target interactions: drug-
target residence time and its impact on efficacy and safety. Expert Opin.
Drug Discovery 2010, 5, 305−310.
(8) (a) Dowling, M. R.; Charlton, S. J. Quantifying the association
and dissociation rates of unlabelled antagonists at the muscarinic M3
receptor. Br. J. Pharmacol. 2006, 148, 927−937. (b) Van Liefde, I.;
Vauquelin, G. Sartan−AT1 receptor interactions: In vitro evidence for
insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol.
2008, 302, 237−243.
(9) Daboun, H. A.; El-Reedy, A. M. A one step synthesis of new 4-
aminopyrimidine derivatives: preparation of tetrazolo- and s-
triazolopyrimidines. Z. Naturforsch. 1983, 38b, 1686−1689.
(10) Mahmood, M.; Aliabadi, A.; Emami, S.; Safavi, M.; Rajabalian,
S.; Ohagheghi, M.-A.; Khoshzaban, A.; Samzadeh-Kermani, A.; Lamei,
N.; Shafiee, A.; Foroumadi, A. Synthesis and in-vitro cytotoxicity of
poly-functionalized 4-(2-arylthiazol-4-yl)-4H-chromenes. Arch. Pharm.
Chem. Life Sci. 2010, 343, 411−416.
(11) Freiberg, C.; Knezevic, I.; Krahn, T.; Ziegelbauer, K.; Braun, M.;
Diedrichs, N. Use of adenosine A1 receptor agonists for the protection
of renal cells against toxic effects caused by aminoglycosides during
treatment of infectious diseases. WO2007/073855 A1, July 5, 2007.
(12) Weikert, R. J.; Bingham, S., Jr.; Emanuel, M. A.; Fraser-Smith, E.
B.; Loughhead, D. G.; Nelson, P. H.; Poulton, A. L. Synthesis and
anthelmintic activity of 3′-benzoylurea derivatives of 6-phenyl-2,3,5,6-
tetrahydroimidazo[2,1-b]thiazole. J. Med. Chem. 1991, 34, 1630−1633.
(13) Crane, L. J.; Anastassiadou, M.; Stigliani, J.-L.; Baziard-
Mouysset, G.; Payard, M. Reactions of some ortho and para
halogenated aromatic nitriles with ethylenediamine: selective synthesis
of imidazolines. Tetrahedron 2004, 60, 5325−5330.
(23) Albrecht-Kupper, B. E.; Leineweber, K.; Nell, P. G. Partial
adenosine A1 receptor agonists for cardiovascular therapies. Purinergic
Signalling 2012, 8, 91−99.
̈
(24) (a) The values for π were either derived from the Craig plot or
survey of Hammett substituent constants and resonance and field
parameters. Chem. Rev. 1991, 91, 165−195.
(25) Dynes, J. J.; Baudais, F. L.; Boyd, R. K. Inter-ring dihedral angles
in polychlorinated biphenyls from photoelectron spectroscopy. Can. J.
Chem. 1985, 63, 1292−1299.
(26) Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis
in Chemistry and Biology; Wiley-Interscience: New York, 1979.
(27) Alonso, M; Herradon, B. A universal scale of aromaticity for π-
organic compounds. J. Comput. Chem. 2010, 31, 917−928.
(28) Lane, J. R.; Klein Herenbrink, C.; van Westen, G. J. P.;
Spoorendonk, J. A.; Hoffmann, C.; IJzerman, A. P. A novel nonribose
agonist, LUF5834, engages residues that are distinct from those of
adenosine-like ligands to activate the adenosine A2A receptor. Mol.
Pharmacol. 2012, 81, 475−487.
(29) Miller, D. C.; Lunn, G.; Jones, P.; Sabnis, Y.; Davies, N. L.;
Driscoll, P. Investigation of the effect of molecular properties on the
binding kinetics of a ligand to its biological target. MedChemComm
2012, 3, 449−452.
(30) Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao,
Z.-G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound
human A2A adenosine receptor. Science 2011, 332, 322−327.
(31) (a) Kruse, A. C.; Hu, J.; Pan, A. C.; Arlow, D. H.; Rosenbaum,
D. M.; Rosemond, E.; Green, H. F.; Liu, T.; Chae, P. S.; Dror, R. O.;
Shaw, D. E.; Weis, W. I.; Wess, J.; Kobilka, B. K. Structure and
dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012,
482, 552−556. (b) Dror, R. O.; Pan, A. C.; Arlow, D. H.; Borhani, D.
W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D. E. Pathway and
mechanism of drug binding to G-protein-coupled receptors. Proc. Natl.
Acad. Sci. U.S.A. 2011, 108, 13118−13123. (c) Selvam, B.;
Wereszczynski, J.; Tikhonova, I. G. Comparison of dynamics of
extracellular accesses to the β1 and β2 adrenoceptors binding sites
uncovers the potential of kinetic basis of antagonist selectivity. Chem.
Biol. Drug Des. 2012, 80, 215−226.
(14) Kaboudin, B.; Elhamifar, D. Phosphorus pentasulfide: A mild
and versatile reagent for the preparation of thioamides from nitriles.
Synthesis 2006, 2006, 224−226.
(15) Palmer, J. T.; Bryant, C. D.; Wang, D.; Davis, D. E.; Setti, E. L.;
Rydzewski, R. M.; Venkatraman, S.; Tian, Z.; Burril, L. C.; Mendonca,
R. V.; Springman, E.; McCarter, J.; Chung, T.; Cheung, H.; Janc, J. W.;
McGrath, M.; Somoza, J. R.; Enriquez, P.; Yu, Z. W.; Strickley, R. M.;
Liu, L.; Venuti, M. C.; Percival, M. D.; Falgueyret, J.; Prasit, P.; Oballa,
R.; Riendeau, D.; Young, R. N.; Wesolowski, G.; Rodan, S. B.;
Johnson, C.; Kimmel, D. N.; Rodan, G. Design and synthesis of tri-ring
P3 benzamide-containing aminonitriles as potent, selective, orally
effective inhibitors of cathepsin K. J. Med. Chem. 2005, 48, 7520−7534.
(16) Lohse, M. J.; Klotz, K. N.; Lindenborn-Fotinos, J.; Reddington,
M.; Schwabe, U.; Olsson, R. A. 8-Cyclopentyl-1,3-dipropylxanthine
(DPCPX) − a selective high affinity antagonist radioligand for A1
adenosine receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1987,
336, 204−210.
(32) Moos, W. H.; Szotek, D. S.; Bruns, R. F. N6-Cyclo-
aklyladenosines. Potent, A1 selective adenosine agonists. J. Med.
Chem. 1985, 28, 1383−1384.
(33) Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.;
Linden, J. International Union of Pharmacology. XXV. Nomenclature
and classification of adenosine receptors. Pharmacol. Rev. 2001, 264,
527−552.
(34) Guo, D.; Mulder-Krieger, T.; IJzerman, A. P.; Heitman, L. H.
Functional efficacy of adenosine A2A receptor agonists is positively
correlated to their receptor residence time. Br. J. Pharmacol. 2012, 166,
1846−1859.
(17) Guo, D.; van Dorp, E. J.; Mulder-Krieger, T.; van Veldhoven, J.
P.; Brussee, J.; IJzerman, A. P.; Heitman, L. H. Dual-point competition
association assay: A fast and high-throughput kinetic screening method
for assessing ligand-receptor binding kinetics. J. Biomol. Screening 2013,
18, 309−320.
(35) Sykes, D. A.; Dowling, M. R.; Charlton, S. J. Exploring the
mechanism of agonist efficacy: a relationship between efficacy and
agonist dissociation rate at the muscarinic M3 receptor. Mol.
Pharmacol. 2009, 76, 543−551.
(18) Bayer Healthcare AG clinical trial report BAY 68-4986/12679.
(19) Unpublished results. Capadenoson was synthesized according to
the procedure reported by Bayer AG in ref 11.
(36) Chang, L. C. W.; Spanjersberg, R. F.; von Frijtag Drabbe
Kunzel, J. K.; Mulder-Krieger, T.; van den Hout, G.; Beukers, M. W.;
̈
(20) Alexander, S. P. H.; Millns, P. J. [3H]ZM241385−an antagonist
for adenosine A2A receptors in rat brain. Eur. J. Pharmacol. 2001, 411,
205−210.
Brussee, J.; IJzerman, A. P. 2,4,6-Trisubstituted pyrimidines as a new
class of selective adenosine A1 receptor antagonists. J. Med. Chem.
2004, 47, 6529−6540.
(37) Cusack, N. J.; Hourani, S. M. 5′-N-Ethylcarboxamidoadenosine:
a potent inhibitor of human platelet aggregation. Br. J. Pharmacol.
1981, 72, 443−447.
(21) Borrmann, T.; Hinz, S.; Bertarelli, D. C. G.; Li, W.; Florin, N.
C.; Scheiff, A. B.; Muller, C. E. 1-alkyl-8-(piperazine-1-sulfonyl)-
̈
phenylxanthines: development and characterization of adenosine A2B
receptor antagonists and a new radioligand with subnanomolar affinity
and subtype specificity. J. Med. Chem. 2009, 52, 3994−4006.
(38) Motulsky, H. J.; Mahan, L. C. The kinetics of competitive
radioligand binding predicted by the law of mass action. Mol.
Pharmacol. 1984, 25, 1−9.
(22) Muller, C. E.; Diekmann, M.; Thorand, M.; Ozola, V. [3H]8-
̈
Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-
purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radio-
ligand for human A3 adenosine receptors. Bioorg. Med. Chem. Lett.
2002, 12, 501−503.
3222
dx.doi.org/10.1021/jm401643m | J. Med. Chem. 2014, 57, 3213−3222